KALV
KalVista Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.00
+0.00%Margins
Gross margin
91.4%
EBITDA margin
-21.0%
EBIT margin
-27.9%
Net margin
-17.9%
FCF margin
15.9%
1460.8%
Return on equity
-11.8%
Return on assets
-21.9%
Return on invested capital
0.66x
Asset turnover
$36.5M
Cash from operations
$5.64
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026